GlaxoSmithKline (GSK.L) has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. The move is part of a reshaping of the drugmaker’s business, which also involves a major asset swap deal struck last month with Novartis (NOVN.VX). Chief Executive Andrew Witty said last month that Britain’s biggest pharmaceuticals company could dispose of individual medicines or a broader portfolio of older established products.
Help employers find you! Check out all the jobs and post your resume.
